Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025Journal of Cancer Research and PracticeOpen Access

Pembrolizumab as an Unconventional First-line Salvage Therapy in Primary Mediastinal Large B-cell Lymphoma: A Case Report

View Full Paper
Ask AI
Bookmark
Share

Authors

SYShuna YaoYKYu‐Hsuan Kuo

Discussion

Loading...

Member takes

Overview

Case report shows pembrolizumab achieved complete response in patient with primary mediastinal large B-cell lymphoma, suggesting efficacy of immune checkpoint inhibitors.

Key Points

  • Pembrolizumab monotherapy led to a complete response after R-CEOP failure over 24 months.
  • Patient reported adverse effects from initial treatment, prompting shift to pembrolizumab.
  • Case highlights the potential clinical value of immune checkpoint inhibitors in aggressive lymphomas.
  • Significant complications were observed, yet therapeutic response remained excellent.

Cite This Study

Yao et al. (2025) studied this question.

synapsesocial.com/papers/68af782c7567bf4f94ff09fbhttps://doi.org/10.4103/ejcrp.ejcrp-d-25-00011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refractory/relapsed primary mediastinal large B-cell lymphoma: a changing paradigm for drug therapy2025
  2. 2A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025
  3. 3Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial2025
  4. 4Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  5. 5primary mediastinal B-cell lymphoma: Survival trends and statistics2025